StockNews.com upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday morning.
Several other analysts also recently commented on the company. Scotiabank initiated coverage on Adaptimmune Therapeutics in a research note on Thursday, May 30th. They set a sector outperform rating and a $3.15 price objective for the company. Mizuho decreased their price target on Adaptimmune Therapeutics from $9.00 to $3.00 and set a buy rating for the company in a report on Friday, May 17th. Finally, HC Wainwright reiterated a buy rating and set a $4.00 price target on shares of Adaptimmune Therapeutics in a research note on Tuesday.
Get Our Latest Stock Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Stock Down 0.9 %
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last announced its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative net margin of 890.13% and a negative return on equity of 259.68%. The business had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $4.40 million. Equities analysts expect that Adaptimmune Therapeutics will post -0.55 EPS for the current fiscal year.
Institutional Investors Weigh In On Adaptimmune Therapeutics
Several institutional investors have recently modified their holdings of the company. Columbia Advisory Partners LLC acquired a new position in Adaptimmune Therapeutics during the first quarter worth $25,000. JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Adaptimmune Therapeutics in the 1st quarter worth about $41,000. Twin Focus Capital Partners LLC acquired a new stake in Adaptimmune Therapeutics in the 4th quarter valued at about $44,000. Boulder Hill Capital Management LP purchased a new position in Adaptimmune Therapeutics during the 1st quarter valued at about $143,000. Finally, Renaissance Technologies LLC raised its position in Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after acquiring an additional 394,566 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
- Five stocks we like better than Adaptimmune Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Pros And Cons Of Monthly Dividend Stocks
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Do ETFs Pay Dividends? What You Need to Know
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.